Literature DB >> 8376934

Immature surface Ig+ B cells can continue to rearrange kappa and lambda L chain gene loci.

A Rolink1, U Grawunder, D Haasner, A Strasser, F Melchers.   

Abstract

Pro and pre B cells possess the long-term capacity to proliferate in vitro on stromal cells and interleukin 7 (IL-7) and can differentiate to surface immunoglobulin (sIg+) cells upon removal of IL-7 from the cultures. A key event in this differentiation is the extensive cell loss due to apoptosis. Because the proto-oncogene bcl-2 can promote cell survival, we established pre-B cell lines from E mu-bcl-2 transgenic mice. These pre-B cells have the same properties as those derived from non-bcl-2 transgenic mice except that they do not die by apoptosis. This allowed us to study the fate of newly formed B cells in vitro for a longer period of time. Here we show that early during the differentiation of pre-B cells, upregulation of RAG-1 and RAG-2 expression go hand in hand with rearrangements of the Ig gene loci. Moreover, the newly formed sIg+ B cells continue to express RAG-1 and RAG-2 and continue to rearrange L chain gene loci, even in the absence of proliferation, in an orderly fashion, so that kappa L+ sIg+ cells can become lambda L+ sIg+ or sIg- cells, whereas lambda L+ sIg+ cells can become sIg-, but not kappa L+ sIg+ cells. Thus, deposition of a complete Ig molecule on the surface of a B cell does not automatically stop the Ig-rearrangement machinery.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8376934      PMCID: PMC2191189          DOI: 10.1084/jem.178.4.1263

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  48 in total

1.  RAG-1 and RAG-2, adjacent genes that synergistically activate V(D)J recombination.

Authors:  M A Oettinger; D G Schatz; C Gorka; D Baltimore
Journal:  Science       Date:  1990-06-22       Impact factor: 47.728

2.  Activation of immunoglobulin kappa gene rearrangement correlates with induction of germline kappa gene transcription.

Authors:  M S Schlissel; D Baltimore
Journal:  Cell       Date:  1989-09-08       Impact factor: 41.582

3.  Expression of Bcl-2 and Bcl-2-Ig fusion transcripts in normal and neoplastic cells.

Authors:  W B Graninger; M Seto; B Boutain; P Goldman; S J Korsmeyer
Journal:  J Clin Invest       Date:  1987-11       Impact factor: 14.808

4.  Regulation of bcl-2 proto-oncogene expression during normal human lymphocyte proliferation.

Authors:  J C Reed; Y Tsujimoto; J D Alpers; C M Croce; P C Nowell
Journal:  Science       Date:  1987-06-05       Impact factor: 47.728

5.  Characterization of the protein product of bcl-2, the gene involved in human follicular lymphoma.

Authors:  Y Tsujimoto; N Ikegaki; C M Croce
Journal:  Oncogene       Date:  1987       Impact factor: 9.867

6.  How immunoglobulin V kappa genes rearrange.

Authors:  M A Shapiro; M Weigert
Journal:  J Immunol       Date:  1987-12-01       Impact factor: 5.422

7.  The V(D)J recombination activating gene, RAG-1.

Authors:  D G Schatz; M A Oettinger; D Baltimore
Journal:  Cell       Date:  1989-12-22       Impact factor: 41.582

8.  Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells.

Authors:  D L Vaux; S Cory; J M Adams
Journal:  Nature       Date:  1988-09-29       Impact factor: 49.962

9.  Preferential linkage of bcl-2 to immunoglobulin light chain gene in chronic lymphocytic leukemia.

Authors:  M Adachi; A Tefferi; P R Greipp; T J Kipps; Y Tsujimoto
Journal:  J Exp Med       Date:  1990-02-01       Impact factor: 14.307

10.  Functional immunoglobulin light chain genes are replaced by ongoing rearrangements of germline V kappa genes to downstream J kappa segment in a murine B cell line.

Authors:  S Levy; M J Campbell; R Levy
Journal:  J Exp Med       Date:  1989-07-01       Impact factor: 14.307

View more
  28 in total

1.  B cell receptor expression level determines the fate of developing B lymphocytes: receptor editing versus selection.

Authors:  V Kouskoff; G Lacaud; K Pape; M Retter; D Nemazee
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

Review 2.  Receptor selection in B and T lymphocytes.

Authors:  D Nemazee
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

Review 3.  Double light chain producing lymphocytes: an enigma of allelic exclusion.

Authors:  L Diaw; D Siwarski; K Huppi
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

Review 4.  Allelic exclusion of immunoglobulin genes: models and mechanisms.

Authors:  Christian Vettermann; Mark S Schlissel
Journal:  Immunol Rev       Date:  2010-09       Impact factor: 12.988

5.  Mutation of Tp53 contributes to the malignant phenotype of Abelson virus-transformed lymphoid cells.

Authors:  K C Thome; A Radfar; N Rosenberg
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

Review 6.  Somatic diversification of antibody responses.

Authors:  B Zheng; G Kelsoe; S Han
Journal:  J Clin Immunol       Date:  1996-01       Impact factor: 8.317

7.  Regulation of DNA metabolic enzymes upon induction of preB cell development and V(D)J recombination: up-regulation of DNA polymerase delta.

Authors:  R Jessberger; P Schär; P Robins; E Ferrari; B Riwar; U Hübscher
Journal:  Nucleic Acids Res       Date:  1997-01-15       Impact factor: 16.971

Review 8.  Checkpoints that control B cell development.

Authors:  Fritz Melchers
Journal:  J Clin Invest       Date:  2015-05-04       Impact factor: 14.808

9.  BCL6 is critical for the development of a diverse primary B cell repertoire.

Authors:  Cihangir Duy; J Jessica Yu; Rahul Nahar; Srividya Swaminathan; Soo-Mi Kweon; Jose M Polo; Ester Valls; Lars Klemm; Seyedmehdi Shojaee; Leandro Cerchietti; Wolfgang Schuh; Hans-Martin Jäck; Christian Hurtz; Parham Ramezani-Rad; Sebastian Herzog; Hassan Jumaa; H Phillip Koeffler; Ignacio Moreno de Alborán; Ari M Melnick; B Hilda Ye; Markus Müschen
Journal:  J Exp Med       Date:  2010-05-24       Impact factor: 14.307

10.  Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment.

Authors:  Maria Rehnberg; Mikael Brisslert; Sylvie Amu; Kiandoht Zendjanchi; Gunilla Håwi; Maria I Bokarewa
Journal:  Arthritis Res Ther       Date:  2010-06-08       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.